{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:40Z","timestamp":1786119520175,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/dad.0b013e3181d1e6f0","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T07:06:23Z","timestamp":1276758383000},"page":"665-675","source":"Crossref","is-referenced-by-count":5,"title":["Different Patterns of Expression of the erbB Family of Receptor Tyrosine Kinases in Common Nevi, Dysplastic Nevi, and Primary Malignant Melanomas: An Immunohistochemical Study"],"prefix":"10.1097","volume":"32","author":[{"given":"Meora","family":"Feinmesser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Kaganovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cohava","family":"Tzabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Sulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elimelech","family":"Okon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210202","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network.","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R2-5-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1006107016969","article-title":"The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.","volume":"52","author":"Gullick","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"R3-5-20210202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0960-9776(95)90022-5","article-title":"Type 1 growth factor receptors: an overview of recent developments.","volume":"4","author":"Mason","year":"1995","journal-title":"Breast"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.onc.1201642","article-title":"The oncogenic erbB-2\/erbB3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.","volume":"16","author":"Pinkas-Kramarski","year":"1998","journal-title":"Oncogene"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB is a common auxillary subunit of NDF- and EGF-receptors: implications for breast cancer.","volume":"15","author":"Karunagaran","year":"1996","journal-title":"EMBO"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1659742","article-title":"Growth factors and cancer.","volume":"254","author":"Aaronson","year":"1991","journal-title":"Science"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3181\/00379727-206-43746","article-title":"Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors.","volume":"206","author":"Ben-Baruch","year":"1994","journal-title":"Proc Soc Exp Biol Med"},{"key":"R8-5-20210202","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1074\/jbc.270.17.9982","article-title":"Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the erbB family of receptor tyrosine kinases.","volume":"270","author":"Karunagaran","year":"1995","journal-title":"J Biol Chem"},{"key":"R9-5-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/cgt.2008.15","article-title":"The ERBB3 receptor in cancer and cancer gene therapy.","volume":"15","author":"Sithanandam","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"R10-5-20210202","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-5-20210202","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1073\/pnas.92.8.3353","article-title":"Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake.","volume":"92","author":"Hurwitz","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.bjc.6602184","article-title":"Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.","volume":"91","author":"Abd El-Rehim DM, Pinder","year":"2004","journal-title":"Br J Cancer"},{"key":"R13-5-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/msb4100195","article-title":"Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.","volume":"3","author":"Amit","year":"2007","journal-title":"Mol Syst Biol"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"R15-5-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0625.2001.100504.x","article-title":"Regulation of epidermal growth factor receptor expression in human melanocytes.","volume":"10","author":"Gordon-Thomson","year":"2001","journal-title":"Exp Dermatol"},{"key":"R16-5-20210202","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/1523-1747.ep12616793","article-title":"Increasing epidermal growth factor receptor expression in human melanocytic tumor progression.","volume":"99","author":"De Wit","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R17-5-20210202","first-page":"5091","article-title":"Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.","volume":"49","author":"Elder","year":"1986","journal-title":"Cancer Res"},{"key":"R18-5-20210202","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0190-9622(92)70219-6","article-title":"Increased epidermal growth factor receptors in melanocytic lesions.","volume":"27","author":"Ellis","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R19-5-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1440-0960.1999.00310.x","article-title":"Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization.","volume":"40","author":"Sparrow","year":"1999","journal-title":"Australas J Dermatol"},{"key":"R20-5-20210202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CMR.0b013e3282f32517","article-title":"Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.","volume":"18","author":"Akslen","year":"2008","journal-title":"Melanoma Res"},{"key":"R21-5-20210202","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1523-1747.2003.12522.x","article-title":"The heregulin\/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.","volume":"121","author":"Stove","year":"2003","journal-title":"J Invest Dermatol"},{"key":"R22-5-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00008390-200502000-00005","article-title":"ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.","volume":"15","author":"Gordon-Thomson","year":"2005","journal-title":"Melanoma Res"},{"key":"R23-5-20210202","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ijc.2910560308","article-title":"Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics.","volume":"56","author":"Natali","year":"1994","journal-title":"Int J Cancer"},{"key":"R24-5-20210202","first-page":"517","article-title":"Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy.","volume":"16","author":"Bodey","year":"1996","journal-title":"Anticancer Res"},{"key":"R25-5-20210202","first-page":"1965","article-title":"Amplification and overexpression of HER-2\/neu are uncommon in advanced stage melanoma.","volume":"20","author":"Persons","year":"2000","journal-title":"Anticancer Res"},{"key":"R26-5-20210202","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jso.10297","article-title":"Absence of HER2 overexpression in metastatic malignant melanoma.","volume":"84","author":"Inman","year":"2003","journal-title":"J Surg Oncol"},{"key":"R27-5-20210202","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-3163-2-8","article-title":"Immunohistochemical determination of HER-2neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications.","volume":"16","author":"Potti","year":"2003","journal-title":"J Carcinog"},{"key":"R28-5-20210202","first-page":"2793","article-title":"No evidence for c-erbB-2 overexpression in cutaneous melanoma.","volume":"21","author":"Fink-Puches","year":"2001","journal-title":"Anticancer Res"},{"key":"R29-5-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.cmr.0000130874.33504.2f","article-title":"Her2\/neu is not a commonly expressed therapeutic target in melanoma- a large cohort tissue microarray study.","volume":"14","author":"Kluger","year":"2004","journal-title":"Melanoma Res"},{"key":"R30-5-20210202","first-page":"471","article-title":"Differential expression of cerbB3 in naevi and malignant melanomas.","volume":"16","author":"Korabiowska","year":"1996","journal-title":"Anticancer Res"},{"key":"R31-5-20210202","first-page":"1319","article-title":"Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanoma and breast carcinomas.","volume":"17","author":"Bodey","year":"1997","journal-title":"Anticancer Res"},{"key":"R32-5-20210202","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.jid.5700543","article-title":"A web-based data warehouse on gene expression in human malignant melanoma.","volume":"127","author":"Gyorffy","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R33-5-20210202","first-page":"973","article-title":"HER3 expression in cutaneous tumors.","volume":"28","author":"Wimmer","year":"2008","journal-title":"Anticancer Res"},{"key":"R34-5-20210202","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma.","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R36-5-20210202","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"R37-5-20210202","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.2910400520","article-title":"Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors.","volume":"40","author":"Rodeck","year":"1987","journal-title":"Int J Cancer"},{"key":"R38-5-20210202","first-page":"179","article-title":"Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediary lesions.","volume":"1","author":"Kath","year":"1990","journal-title":"Cancer Ther Control"},{"key":"R39-5-20210202","first-page":"4726","article-title":"Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation.","volume":"46","author":"Real","year":"1986","journal-title":"Cancer Res"},{"key":"R40-5-20210202","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1034\/j.1600-0560.2002.290807.x","article-title":"Melanoma associated with pseudoepitheliomatous hyperplasia: a case series and investigation into the role of epidermal growth factor receptor.","volume":"29","author":"Mott","year":"2002","journal-title":"J Cutan Pathol"},{"key":"R41-5-20210202","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00000372-199610000-00003","article-title":"Expression of nerve growth factor and epidermal growth factor receptors in neural nevi with nevic corpuscles.","volume":"18","author":"Argenyi","year":"1996","journal-title":"Am J Dermatopathol"},{"key":"R42-5-20210202","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.neo.7900156","article-title":"Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.","volume":"3","author":"Udart","year":"2001","journal-title":"Neoplasia"},{"key":"R43-5-20210202","first-page":"1483","article-title":"Nuclear expression of the c-erbB-4\/HER-4 growth factor receptor in invasive breast cancers.","volume":"60","author":"Srinivasan","year":"2000","journal-title":"Cancer Res"},{"key":"R44-5-20210202","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/bcr1394","article-title":"HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.","volume":"8","author":"Tovey","year":"2006","journal-title":"Breast Cancer Res"},{"key":"R45-5-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1523-1747.ep12358440","article-title":"Novel mutations of the KIT (mast-stem cell growth factor receptor) proto-oncogene in human piebaldism.","volume":"101","author":"Spritz","year":"1993","journal-title":"J Invest Dermatol"},{"key":"R46-5-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.2910520207","article-title":"Progression of human cutaneous melanoma is associated with loss of expression of c-Kit proto-oncogene receptor.","volume":"52","author":"Natali","year":"1992","journal-title":"Int J Cancer"},{"key":"R47-5-20210202","first-page":"2221","article-title":"KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cell lines.","volume":"8","author":"Zakut","year":"1993","journal-title":"Oncogene"},{"key":"R48-5-20210202","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archderm.139.12.1620","article-title":"Cutaneous melanomas associated with nevi.","volume":"139","author":"Bevona","year":"2003","journal-title":"Arch Dermatol"},{"key":"R49-5-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00008390-200204000-00006","article-title":"Overexpression of HER-2 in thick melanoma.","volume":"12","author":"Eliopoulos","year":"2002","journal-title":"Melanoma Res"},{"key":"R50-5-20210202","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.163.2.1037","article-title":"Identification of new HER2\/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.","volume":"163","author":"Rongcun","year":"1999","journal-title":"J Immunol"},{"key":"R51-5-20210202","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1054\/bjoc.2001.2089","article-title":"Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.","volume":"85","author":"Sotiriadou","year":"2001","journal-title":"Br J Cancer"},{"key":"R52-5-20210202","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s002620100225","article-title":"HER-2\/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4 (+) T cell clones.","volume":"50","author":"Perez","year":"2002","journal-title":"Cancer Immunol Immunother"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000372-201010000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:25:39Z","timestamp":1786040739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000372-201010000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0b013e3181d1e6f0","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}